Methyl 5- aminolevulinate
was used as the photosensitiser and only two treatments were given, one week apart.
5-Aminolevulinic acid (ALA) and its derivative methyl aminolevulinate
(ME-ALA) are the photosensitizing precursor agents most widely used in clinical practice.
Rhodes LE, de Rie M, Enstrom Y et al: Photodynamic therapy using topical methyl aminolevulinate
dehydratase activity asa lead marker in patients with chronic renal failure.
Classification and main clinical features of the porphyrias [Taken from: Kauppinen, 2005] Type of Main Clinical Porphyria Symptoms Acute Porphyrias Acute Intermittent Porphyria Acute Attacks Hereditary Coproporphyria Acute attacks and skin fragility Variegate Porphyria Acute attacks and skin fragility Aminolevulinate
Acute attacks and/or Dehydratase peripheral neuropathy Deficiency Porphyria Non Acute Porphyrias Congenital Erythropoietic Severe photosensitivity Porphyria and haemolysis Erythropoietic Photosensitivity Protoporphyria and liver damage Porphyria Cutanea Tarda Skin fragility and chronic liver disease Table 2.
For example, the labeling for methyl aminolevulinate
(MAL)--approved as Metvix for topical PDT throughout Europe and Australia, and believed to soon be headed for U.
Designated ALN-AS1, an RNAi Therapeutic Targeting Aminolevulinate
Synthase 1 (ALAS-1) for the Treatment of Acute Intermittent Porphyria (AIP) as a New Program in the "Alnylam 5x15" Product Strategy.
fluorescence cystoscopy: new diagnostic tool for photodiagnosis of superficial bladder cancer-a multicenter study.
Alnylam) announced that it is advancing its Development Candidate for ALN-AS1, an RNAi therapeutic targeting aminolevulinate
synthase-1 (ALAS-1) for the treatment of hepatic porphyrias including acute intermittent porphyria (AIP).
For example, the binding of IRP to IREs found in the 5' UTR of mRNAs encoding ferritin, ferroportin, and the haem biosynthetic enzyme, aminolevulinate
synthase interferes with the initiation of translation.
and PhotoCure ASA announced today that they have entered into a Mediation Agreement designed to facilitate resolution of the parties' potential patent disputes concerning PhotoCure and Galderma's methyl aminolevulinate
Association between aminolevulinate
dehydrogenase genotype and blood lead levels in Taiwan.